{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:31Z","timestamp":1791475411884,"version":"4.3.4"},"reference-count":258,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtho.2025.06.028","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:21:10Z","timestamp":1751563270000},"page":"1392-1422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["50 Years of Progress in NSCLC: A New Fellow\u2019s Guide in the Clinic"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abesh","family":"Niroula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Uprety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smeltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Geissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond U.","family":"Osarogiagbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Mino-Kenudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Jiyeong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Hegi-Johnson Franzcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagashree","family":"Seetharamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.06.028_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s11606-024-08786-8","article-title":"Effectiveness of very brief advice on tobacco cessation: A systematic review and meta-analysis","volume":"39","author":"Cheng","year":"2024","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib3","first-page":"CD001292","article-title":"Individual behavioural counselling for smoking cessation","volume":"3","author":"Lancaster","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2025.06.028_bib4","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.121.211801","article-title":"Combination of the searches for pair-produced vectorlike partners of the third-generation quarks at sqrt[s]=13 TeV with the ATLAS detector","volume":"121","author":"Aaboud","year":"2018","journal-title":"Phys Rev Lett"},{"key":"10.1016\/j.jtho.2025.06.028_bib5","article-title":"Nicotine replacement therapy versus control for smoking cessation","volume":"5","author":"Hartmann-Boyce","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2025.06.028_bib6","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","volume":"5","author":"Hajizadeh","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2025.06.028_bib7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib8","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s12094-023-03308-0","article-title":"An overview on the relationship between residential radon and lung cancer: what we know and future research","volume":"25","author":"Ruano-Ravina","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.06.028_bib10","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.jtho.2023.06.018","article-title":"Low-dose computed tomography screening in relatives with a family history of lung cancer","volume":"18","author":"Wang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib11","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1200\/JCO.23.01372","article-title":"Germline EGFR mutations and familial lung cancer","volume":"41","author":"Oxnard","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"National Lung Screening Trial Research Team","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ijc.32486","article-title":"Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial","volume":"146","author":"Becker","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2025.06.028_bib15","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/JTO.0b013e31829fd3d5","article-title":"Screening high-risk populations for lung cancer: guideline recommendations","volume":"8","author":"Roberts","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jtho.2022.09.220","article-title":"Potential impact of criteria modifications on race and sex disparities in eligibility for lung cancer screening","volume":"18","author":"Smeltzer","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jama.2021.0377","article-title":"Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"325","author":"Jonas","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2025.06.028_bib18","first-page":"50","article-title":"Screening for lung cancer: 2023 guideline update from the American Cancer Society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2025.06.028_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJMoa1211776","article-title":"Selection criteria for lung-cancer screening","volume":"368","author":"Tammem\u00e4gi","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/JTO.0b013e31824ab6b0","article-title":"A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening","volume":"7","author":"Bigbee","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.22.01345","article-title":"Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography","volume":"41","author":"Mikhael","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2213-2600(23)00338-7","article-title":"Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study","volume":"12","author":"Chang","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2017161659","article-title":"Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017","volume":"284","author":"MacMahon","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2025.06.028_bib24","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.21.02496","article-title":"Lung cancer diagnosed through screening, lung nodule, and neither program: a prospective observational study of the detecting early lung cancer (DELUGE) in the Mississippi Delta cohort","volume":"40","author":"Osarogiagbon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib25","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.chest.2022.12.006","article-title":"Pulmonary nodules, lung cancer screening, and lung cancer in the medicare population","volume":"163","author":"Pinsky","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.06.028_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JTO.0b013e31823c58ab","article-title":"International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report","volume":"7","author":"Field","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/JTO.0000000000000210","article-title":"Patient-centered outcomes among lung cancer screening recipients with computed tomography: a systematic review","volume":"9","author":"Slatore","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JTO.0b013e31807a2f81","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"2","author":"Rami-Porta","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib31","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC mesothelioma staging project: improving staging of a rare disease through international participation","volume":"11","author":"Pass","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2025.06.028_bib32","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/JTO.0000000000000559","article-title":"The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer","volume":"10","author":"Rami-Porta","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/JTO.0b013e31811f4703","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer","volume":"2","author":"Postmus","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC Lung Cancer Staging Project: Proposals for the revision of the M Descriptors in the forthcoming eighth edition of the TNM Classification of Lung Cancer","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jtho.2022.12.009","article-title":"The International Association for the Study of Lung Cancer lung cancer staging project: overview of challenges and opportunities in revising the nodal classification of lung cancer","volume":"18","author":"Osarogiagbon","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","article-title":"The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer","volume":"4","author":"Rusch","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/JTO.0b013e31807ec803","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer","volume":"2","author":"Rusch","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib39","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jtho.2023.10.012","article-title":"The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","volume":"19","author":"Huang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib40","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/JTO.0b013e3181b27799","article-title":"The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"4","author":"Valli\u00e8res","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib41","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/JTO.0b013e31818b06e3","article-title":"The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer","volume":"3","author":"Travis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa0900043","article-title":"Preoperative staging of lung cancer with combined PET-CT","volume":"361","author":"Fischer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib43","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/jama.2010.1705","article-title":"Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial","volume":"304","author":"Annema","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2025.06.028_bib44","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jtcvs.2011.08.037","article-title":"A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer","volume":"142","author":"Yasufuku","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-2600(16)30317-4","article-title":"Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis","volume":"4","author":"Korevaar","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib46","first-page":"3805","article-title":"Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer: a randomized clinical trial","volume":"41","author":"Bousema","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib47","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jtho.2021.03.003","article-title":"The International Association for the Study of Lung Cancer molecular database project: objectives, challenges, and opportunities","volume":"16","author":"Osarogiagbon","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib48","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jtcvs.2010.11.008","article-title":"Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 trial","volume":"141","author":"Darling","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2017.2993","article-title":"Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent","volume":"4","author":"Smeltzer","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib50","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jtho.2024.03.021","article-title":"The International Association for the Study of Lung Cancer lung cancer staging project: proposals for revision of the classification of residual tumor after resection for the forthcoming (ninth) edition of the TNM classification of lung cancer","volume":"19","author":"Detterbeck","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jtho.2019.10.019","article-title":"The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer","volume":"15","author":"Edwards","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtho.2019.11.009","article-title":"Beyond margin status: population-based validation of the proposed International Association for the Study of Lung Cancer residual tumor classification recategorization","volume":"15","author":"Osarogiagbon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib53","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jtho.2020.09.006","article-title":"Complete resection in lung cancer surgery: from definition to validation and beyond","volume":"15","author":"Rami-Porta","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ejcts.2006.08.008","article-title":"ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer","volume":"30","author":"Lardinois","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.athoracsur.2021.05.051","article-title":"American College of Surgeons Commission on Cancer standard for curative-intent pulmonary resection","volume":"113","author":"Nissen","year":"2022","journal-title":"Ann Thorac Surg"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2025.06.028_bib56","first-page":"S304","article-title":"Transthoracic needle biopsy of the lung","volume":"7","author":"DiBardino","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.06.028_bib57","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1378\/chest.117.4.1049","article-title":"Diagnostic yield of fiberoptic bronchoscopy in evaluating solitary pulmonary nodules","volume":"117","author":"Baaklini","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.06.028_bib58","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jtho.2018.11.013","article-title":"Electromagnetic navigation bronchoscopy for peripheral pulmonary lesions: one-year results of the prospective, multicenter NAVIGATE study","volume":"14","author":"Folch","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib59","article-title":"Navigational Bronchoscopy versus Computed Tomography-guided Transthoracic Needle Biopsy for the Diagnosis of Indeterminate Lung Nodules: protocol and rationale for the Veritas multicenter randomized trial","author":"Lentz","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jtho.2025.06.028_bib60","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa2414059","article-title":"Navigational bronchoscopy or transthoracic needle biopsy for lung nodules","volume":"392","author":"Lentz","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/resp.14626","article-title":"Mobile cone-beam computed tomography complementing shape-sensing robotic-assisted bronchoscopy in the small pulmonary nodule sampling: a multicentre experience","volume":"29","author":"Abia-Trujillo","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.jtho.2025.06.028_bib62","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/resp.14778","article-title":"First-in-human use of a new robotic electromagnetic navigation bronchoscopic platform with integrated Tool-in-Lesion Tomosynthesis (TiLT) technology for peripheral pulmonary lesions: the Frontier study","volume":"29","author":"Saghaie","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.jtho.2025.06.028_bib63","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3390\/diagnostics14171955","article-title":"Improving shape-sensing robotic-assisted bronchoscopy outcomes with mobile cone-beam computed tomography guidance","volume":"14","author":"Bashour","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtho.2025.06.028_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/resp.14368","article-title":"Robotic-assisted bronchoscopy versus CT-guided transthoracic biopsy for diagnosis of pulmonary nodules","volume":"28","author":"Yu Lee-Mateus","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.jtho.2025.06.028_bib65","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/imj.15833","article-title":"Cryobiopsy with radial-endobronchial ultrasound (Cryo-Radial) has comparable diagnostic yield with higher safety in comparison to computed tomography-guided transthoracic biopsy for peripheral pulmonary lesions: an exploratory randomised study","volume":"53","author":"Herath","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtho.2025.06.028_bib66","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ejca.2013.02.008","article-title":"Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a meta-analysis","volume":"49","author":"Zhang","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.06.028_bib67","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.21037\/jtd-24-178","article-title":"Cone-beam computed tomography-guided shape-sensing robotic bronchoscopy vs. electromagnetic navigation bronchoscopy for pulmonary nodules","volume":"16","author":"Abdelghani","year":"2024","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.06.028_bib68","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/LBR.0000000000000509","article-title":"Sampling utility of the convex probe endobronchial ultrasound visible intrapulmonary lesion","volume":"25","author":"Almeida","year":"2018","journal-title":"J Bronchology Interv Pulmonol"},{"key":"10.1016\/j.jtho.2025.06.028_bib69","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1378\/chest.15-1216","article-title":"Technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration: CHEST guideline and expert panel report","volume":"149","author":"Wahidi","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.06.028_bib70","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1378\/chest.14-1526","article-title":"Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life","volume":"147","author":"Ost","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.06.028_bib71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.chest.2024.06.3804","article-title":"Management of central airway obstruction: an American College of Chest Physicians clinical practice guideline","volume":"167","author":"Mahmood","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.06.028_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00980-2019","article-title":"The Pleural Effusion And Symptom Evaluation (PLEASE) study of breathlessness in patients with a symptomatic pleural effusion","volume":"55","author":"Muruganandan","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2025.06.028_bib73","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib74","series-title":"Histological Typing of Lung Tumors","year":"1981"},{"key":"10.1016\/j.jtho.2025.06.028_bib75","series-title":"International Histological Classification of Tumours","year":"1999"},{"key":"10.1016\/j.jtho.2025.06.028_bib76","series-title":"WHO Classification of Tumours","article-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","year":"2015"},{"key":"10.1016\/j.jtho.2025.06.028_bib77","series-title":"Thoracic Tumours: WHO Classification of Tumours","year":"2021"},{"key":"10.1016\/j.jtho.2025.06.028_bib78","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1002\/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#","article-title":"Small adenocarcinoma of the lung. Histologic characteristics and prognosis","volume":"75","author":"Noguchi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.06.028_bib79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib80","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1513\/pats.201107-042ST","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary","volume":"8","author":"Travis","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jtho.2025.06.028_bib81","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","article-title":"A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Moreira","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib82","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2021.04.008","article-title":"Validation study of the International Association for the Study of Lung Cancer histologic grading system of invasive lung adenocarcinoma","volume":"16","author":"Rokutan-Kurata","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib83","article-title":"Utility of newly proposed grading system from International Association for the Study of Lung Cancer for invasive lung adenocarcinoma","volume":"2","author":"Kagimoto","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.06.028_bib84","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib85","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.06.028_bib86","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.06.028_bib87","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.06.028_bib88","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib89","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib91","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib92","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib93","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib94","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.06.028_bib95","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib96","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib97","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0360-3016(86)90061-1","article-title":"Impact of tumor control on survival in carcinoma of the lung treated with irradiation","volume":"12","author":"Perez","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2025.06.028_bib98","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM199010043231403","article-title":"A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer","volume":"323","author":"Dillman","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib99","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.06.028_bib100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib101","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib102","series-title":"Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2","author":"Bradley","year":"2024"},{"key":"10.1016\/j.jtho.2025.06.028_bib103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable Stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib104","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2025.06.028_bib106","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib107","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/88.17.1210","article-title":"Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and Leukemia Group B (CALGB) 8433 trial","volume":"88","author":"Dillman","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.06.028_bib108","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2009.04.029","article-title":"A phase I\/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117","volume":"77","author":"Bradley","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2025.06.028_bib109","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ijrobp.2006.02.046","article-title":"Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer","volume":"65","author":"Schild","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2025.06.028_bib110","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable Stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib111","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib112","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib113","article-title":"CheckMate 73L: phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC. ESMO IO","volume":"24","author":"Peters","year":"2024","journal-title":"ESMO IO Tech"},{"key":"10.1016\/j.jtho.2025.06.028_bib114","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3109\/02841869409121782","article-title":"Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects","volume":"33","author":"Lax","year":"1994","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib115","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1062::AID-CNCR8>3.0.CO;2-G","article-title":"Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience","volume":"82","author":"Uematsu","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.06.028_bib116","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jtcvs.2012.10.038","article-title":"Treatment of stage I lung cancer in high risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033)","volume":"145","author":"Crabtree","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib117","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib118","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0022-5223(19)32943-5","article-title":"Pneumonectomy and lobectomy in bronchogenic carcinoma. A comparison of end results of the Overholt and Ochsner clinics","volume":"44","author":"Shimkin","year":"1962","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib119","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0003-4975(95)00537-U","article-title":"Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group","volume":"60","author":"Ginsberg","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib121","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib122","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.semtcvs.2024.11.002","article-title":"Systematic review of sublobar resection for treatment of high-risk patients with stage I non-small cell lung cancer","volume":"37","author":"Merritt","year":"2025","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.06.028_bib123","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.2007.12.6649","article-title":"Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study","volume":"25","author":"Swanson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/THBQ1793","article-title":"Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function: violet RCT","volume":"26","author":"Lim","year":"2022","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jtho.2025.06.028_bib125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2006.08.2826","article-title":"Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)","volume":"25","author":"Rusch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib126","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.1986.4.1.14","article-title":"A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer","volume":"4","author":"Ruckdeschel","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib127","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1200\/JCO.1989.7.11.1602","article-title":"Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group","volume":"7","author":"Bonomi","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.1988.6.4.633","article-title":"Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial","volume":"6","author":"Rapp","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib129","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1200\/JCO.1996.14.10.2774","article-title":"Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer","volume":"14","author":"Crawford","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib130","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study","volume":"16","author":"Wozniak","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib132","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib133","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib134","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib135","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib136","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.22.02545","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"41","author":"Shepherd","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib137","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.22.02546","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib138","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib139","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib140","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib141","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib142","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.3390\/cancers15184648","article-title":"Angiogenesis in lung cancer: understanding the roles of growth factors","volume":"15","author":"Ngaha","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.06.028_bib143","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.06.028_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102545","article-title":"Immunotherapy-based combinations in metastatic NSCLC","volume":"116","author":"Desai","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2025.06.028_bib145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9610","article-title":"Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study. ASCO Annual meeting","author":"Neal","year":"2020"},{"key":"10.1016\/j.jtho.2025.06.028_bib146","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.annonc.2022.01.052","article-title":"43P MRTX-500: phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy","volume":"33","author":"Leal","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib147","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","article-title":"Pembrolizumab with or without lenvatinib for first-line metastatic NSCLC with programmed cell death-ligand 1 tumor proportion score of at least 1% (LEAP-007): a randomized, double-blind, phase 3 trial","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0303-7207(83)90027-8","article-title":"The biochemistry and physiology of the receptor-kinase for epidermal growth factor","volume":"31","author":"Carpenter","year":"1983","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jtho.2025.06.028_bib149","first-page":"2771","article-title":"Recombinant human epidermal growth factor precursor is a glycosylated membrane protein with biological activity","volume":"9","author":"Mroczkowski","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtho.2025.06.028_bib150","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.06.028_bib151","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib152","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib153","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib154","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib156","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib157","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib158","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib159","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib160","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib161","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib162","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib163","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2025.06.028_bib164","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","article-title":"Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study","volume":"20","author":"Yang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib166","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib167","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in Stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib168","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib169","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib170","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, tolerability, and antitumor activity of Zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor Exon 20 insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib171","author":"Wang"},{"key":"10.1016\/j.jtho.2025.06.028_bib172","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions","volume":"18","author":"Han","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib173","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"Tribute: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib174","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib175","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib176","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jtho.2016.11.2225","article-title":"EGFR Mutation Subtypes Influence Survival Outcomes following First-Line gefitinib Therapy in Advanced Asian NSCLC Patients","volume":"12","author":"Sutiman","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib177","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib178","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib179","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","article-title":"Three-year safety, tolerability, and health-related quality of life outcomes of adjuvant osimertinib in patients with resected stage IB to IIIA EGFR-mutated NSCLC: updated analysis from the phase 3 ADAURA trial","volume":"18","author":"John","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib181","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1556-0864(25)00379-X","article-title":"S. Lu SSRMOM-JAXDJC-HYSOKGMA. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): updated overall survival (OS) analysis from the Laura study","volume":"20","author":"Dols","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib182","doi-asserted-by":"crossref","first-page":"19893","DOI":"10.1073\/pnas.0805381105","article-title":"A mouse model for EML4-ALK-positive lung cancer","volume":"105","author":"Soda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.06.028_bib183","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.1158\/0008-5472.CAN-10-1671","article-title":"Inhibition of ALK, PI3K\/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene","volume":"70","author":"Chen","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.06.028_bib184","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-07-6186","article-title":"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors","volume":"68","author":"McDermott","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.06.028_bib185","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib186","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib187","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib188","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib189","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib191","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib192","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.06.028_bib193","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib194","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib195","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib196","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib197","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib198","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib199","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib200","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib201","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMc1415359","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"372","author":"Shaw","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib202","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.06.028_bib203","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib204","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: the phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib206","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-24-0374","article-title":"Unlocking the next frontier in precision oncology: addressing drug-tolerant residual disease","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.06.028_bib207","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtho.2025.06.028_bib208","first-page":"1","article-title":"More to the RAS story: KRASG12C inhibition, resistance mechanisms, and moving beyond KRASG12C","volume":"42","author":"Lietman","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2025.06.028_bib209","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib210","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib211","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2021.07.005","article-title":"On target: rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma","volume":"160","author":"Lindsay","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.06.028_bib212","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib213","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib214","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib215","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/fon-2021-1250","article-title":"Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design","volume":"18","author":"Riely","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib216","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib217","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib218","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib219","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2025.06.028_bib220","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib221","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 gene fusions in solid tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.06.028_bib222","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.20.03307","article-title":"Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry","volume":"39","author":"Drilon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib223","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib224","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib225","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib226","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib227","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib228","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib229","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib231","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib232","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 Poplar and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib233","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib234","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib235","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib236","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib237","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib238","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib239","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib240","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib241","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.06.028_bib242","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib243","first-page":"e14","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib244","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib245","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib246","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.06.028_bib247","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib248","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib249","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib250","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.06.028_bib251","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.06.028_bib252","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.3390\/cancers15143551","article-title":"Specialist palliative care for patients with cancer: more than end-of-life care","volume":"15","author":"Gouldthorpe","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.06.028_bib253","first-page":"195","article-title":"WHO cancer pain relief programme","volume":"7","author":"Stjernsw\u00e4rd","year":"1988","journal-title":"Cancer Surv"},{"key":"10.1016\/j.jtho.2025.06.028_bib254","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0825859788004001-202","article-title":"Controversies in palliative care","volume":"4","author":"Macdonald","year":"1988","journal-title":"J Palliat Care"},{"key":"10.1016\/j.jtho.2025.06.028_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8588(05)70324-5","article-title":"Palliative medicine and the medical oncologist. Defining the purview of care","volume":"10","author":"Cherny","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtho.2025.06.028_bib256","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib257","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200605-587ST","article-title":"An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses","volume":"177","author":"Lanken","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2025.06.028_bib258","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.24.00542","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.06.028_bib259","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.242118","article-title":"Transforming lung cancer screening with AI: comprehensive evaluation and personalized medicine prospects","volume":"312","author":"Yanagawa","year":"2024","journal-title":"Radiology"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425008196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425008196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:23:48Z","timestamp":1790817828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425008196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":258,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1556086425008196"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.06.028","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"50 Years of Progress in NSCLC: A New Fellow\u2019s Guide in the Clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}